A leader in the Greater Philadelphia Life Science Community, promoting industry & academic collaborations, to drive innovative science towards commercialization for the benefit of patients. Retired in 2015 after 35 years with ICI/ AstraZeneca: Jan 2017, appointed  Head of Business Development for NIIMBL (National Institute for Innovation in  Manufacturing Biopharmaceuticals), based at The Biotech Institute at University of Delaware  2009 – present: Chairman of Delaware Bioscience Association (DE Bio). While at  AstraZeneca Chris held global responsibility for External Relations to drive awareness of

AstraZeneca’s areas of partnering interest. Succeeded in establishing AZ as a Preferred  Partner within the biotechnology sector, venture capital & academic community. An expert in technology transfer with over 24 years of experience negotiating strategic alliances, licenses, and academic/industry partnerships at the North America Headquarters of AstraZeneca, in  Wilmington, Delaware.

In 1980 recruited to the Cardio-Renal Pharmacology group of ICI/Zeneca. During 15 years in discovery research, he contributed to the development of numerous marketed therapeutic products, including blockbuster treatments for high blood pressure (Tenormin®), asthma  (Accolate®), and schizophrenia (Seroquel®).

Founding member and Chairman of the Board of the Delaware Bioscience Association.  Former Member of the Executive Committee of the Board of Trustees of the Association of  University Technology Managers (AUTM), and served as Vice President for Eastern US  Region (2006-2007).